DN
Therapeutic Areas
IRLAB Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Mesdopetam (IRL790) | Levodopa-Induced Dyskinesia (PD-LIDs) | Phase IIb |
| Pirepemat (IRL752) | Falls in Parkinson's Disease (PD-Falls) | Phase IIb |
| IRL757 | Apathy in Neurological Disorders (incl. PD) | Phase I |
| IRL942 | Cognitive Impairment in Parkinson's (PD-CI) | Preclinical |
| IRL1117 | Core PD symptoms (once-daily oral) | Preclinical |
Leadership Team at IRLAB Therapeutics
DK
Dr. Kristina Torfgård
Chief Executive Officer (CEO)
GA
Gustaf Albèrt
Chief Financial Officer (CFO)
DC
Dr. Clas Sonesson
Chief Scientific Officer (CSO)
DC
Dr. Carola Lemne
Chairperson of the Board
DC
Dr. Christer Nordstedt
Board Member
DG
Dr. Gunnar Olsson
Board Member
RP
Rein Piir
Board Member
VW
Veronica Wallin
Board Member